Modified by the Innovative Drugs and Strategies—Pattern of Selected Indications for Pediatric Liver Transplantation
Irena Jankowska
Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorPiotr Socha
Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorDorota Gliwicz
Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorCorresponding Author
Patryk Lipiński
Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland
Institute of Clinical Sciences, Maria-Skłodowska-Curie Medical Academy, Warsaw, Poland
Correspondence:
Patryk Lipiński ([email protected])
Search for more papers by this authorDariusz Rokicki
Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorPiotr Kaliciński
Department of Surgery and Organ Transplantation, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorEwa Danielewska
Department of Surgery and Organ Transplantation, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorRyszard Grenda
Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorIrena Jankowska
Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorPiotr Socha
Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorDorota Gliwicz
Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorCorresponding Author
Patryk Lipiński
Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland
Institute of Clinical Sciences, Maria-Skłodowska-Curie Medical Academy, Warsaw, Poland
Correspondence:
Patryk Lipiński ([email protected])
Search for more papers by this authorDariusz Rokicki
Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorPiotr Kaliciński
Department of Surgery and Organ Transplantation, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorEwa Danielewska
Department of Surgery and Organ Transplantation, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorRyszard Grenda
Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland
Search for more papers by this authorABSTRACT
Background
Liver transplantation (LTx) constitutes a major life-saving routine treatment for children with end-stage liver disease. However, the analysis of LTx registries in children provides much information about changes in the indication profiles in the recent years.
Methods
The article provides a comprehensive review about the successes, hopes, and challenges related to changing indications for LTx in children based on the literature review and our own experience. Retrospective review of the indications for LTx at a tertiary referral pediatric hospital was also presented.
Results and Conclusions
In the context of the new therapies that have emerged, the need for LTx has decreased in patients with chronic hepatitis B and C infection and tyrosinemia type 1. In primary hyperoxaluria type 1, new RNAi-based therapy has eliminated the requirement for LTx (both isolated or combined). There is a hope that introduction of ileal bile acid transporter (IBAT) blockers reduces the need for LTx in patients with Alagille syndrome or progressive familial intrahepatic cholestasis. The number of children qualified for LTx with urea cycle disorders (UCDs) as a prophylaxis of neurodevelopmental impairment is increasing.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1U. Baumann, V. Karam, R. Adam, et al., “European Liver and Intestine Transplant Association (ELITA) and All ELTR Contributing Centers. Prognosis of Children Undergoing Liver Transplantation: A 30-Year European Study,” Pediatrics 150 (2022): e2022057424.
- 2D. Haldar, B. Kern, J. Hodson, et al., “European Liver and Intestine Transplant Association (ELITA). Outcomes of Liver Transplantation for Non-Alcoholic Steatohepatitis: A European Liver Transplant Registry Study,” Journal of Hepatology 71 (2019): 313–322.
- 3P. J. McKiernan, A. Ganoza, J. E. Squires, et al., “Evolving Trends in Liver Transplant for Metabolic Liver Disease in the United States,” Liver Transplantation 25 (2019): 911–921.
- 4R. Belostotsky and Y. Frishberg, “Novel Therapeutic Approaches for the Primary Hyperoxalurias,” Pediatric Nephrology 36 (2021): 2593–2606.
- 5T. Cargill and E. Barnes, “Therapeutic Vaccination for Treatment of Chronic Hepatitis B,” Clinical and Experimental Immunology 205 (2021): 106–118.
- 6N. Hadžić, “Metabolic Indications for Pediatric Liver Transplantation: A Slow Train Coming,” Liver Transplantation 25 (2019): 829–830.
- 7E. Holme and S. Lindstedt, “Nontransplant Treatment of Tyrosinemia,” Clinics in Liver Disease 4 (2000): 805–814.
- 8H. W. Lee, J. S. Lee, and S. H. Ahn, “Hepatitis B Virus Cure: Targets and Future Therapies,” International Journal of Molecular Sciences 22 (2020): 213.
- 9S. Vimalesvaran and A. Dhawan, “Liver Transplantation for Pediatric Inherited Metabolic Liver Diseases,” World Journal of Hepatology 13 (2021): 1351–1366.
- 10M. García Vega, J. D. Andrade, A. Morais, et al., “Urea Cycle Disorders and Indications for Liver Transplantation,” Frontiers in Pediatrics 11 (2023): 1103757.
- 11B. M. Kamath, P. Stein, R. H. J. Houwen, and H. J. Verkade, “Potential of Ileal Bile Acid Transporter Inhibition as a Therapeutic Target in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis,” Liver International 40 (2020): 1812–1822.
- 12N. Alkhouri, I. A. Hanouneh, N. N. Zein, et al., “Liver Transplantation for Nonalcoholic Steatohepatitis in Young Patients,” Transplant International 29 (2016): 418–424.
- 13I. Doycheva, D. Issa, K. D. Watt, R. Lopez, G. Rifai, and N. Alkhouri, “Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States,” Journal of Clinical Gastroenterology 52 (2018): 339–346.
- 14J. P. Mann, L. Valenti, E. Scorletti, C. D. Byrne, and V. Nobili, “Nonalcoholic Fatty Liver Disease in Children,” Seminars in Liver Disease 38 (2018): 1–13.
- 15https://apps.who.int/iris/handle/10665/246177. Accessed on 01 June 2023.
- 16https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed on 01 June 2023.
- 17C. Stasi, C. Silvestri, and F. Voller, “Hepatitis B Vaccination and Immunotherapies: An Update,” Clinical and Experimental Vaccine Research 9 (2020): 1–7.
- 18C. J. Alberts, G. M. Clifford, D. Georges, et al., “Worldwide Prevalence of Hepatitis B Virus and Hepatitis C Virus Among Patients With Cirrhosis at Country, Region, and Global Levels: A Systematic Review,” The Lancet Gastroenterology & Hepatology 7 (2022): 724–735.
- 19M. Khatun, R. Ray, and R. B. Ray, “Hepatitis C Virus Associated Hepatocellular Carcinoma,” Advances in Cancer Research 149 (2021): 103–142.
- 20N. Salari, M. Kazeminia, N. Hemati, M. Ammari-Allahyari, M. Mohammadi, and S. Shohaimi, “Global Prevalence of Hepatitis C in General Population: A Systematic Review and Meta-Analysis,” Travel Medicine and Infectious Disease 46 (2022): 102255.
- 21O. Falade-Nwulia, C. Suarez-Cuervo, D. R. Nelson, M. W. Fried, J. B. Segal, and M. S. Sulkowski, “Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review,” Annals of Internal Medicine 166 (2017): 637–648.
- 22J. M. Chinsky, R. Singh, C. Ficicioglu, et al., “Diagnosis and Treatment of Tyrosinemia Type I: A US and Canadian Consensus Group Review and Recommendations,” Genetics in Medicine 19 (2017): 1380–1395.
- 23Y. Tang and Y. Kong, “Hereditary Tyrosinemia Type I: Newborn Screening, Diagnosis and Treatment,” Zhejiang Da Xue Xue Bao. Yi Xue Ban 50 (2021): 514–523.
- 24W. G. van Ginkel, I. L. Rodenburg, C. O. Harding, C. E. M. Hollak, M. R. Heiner-Fokkema, and F. J. van Spronsen, “Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1,” Paediatric Drugs 21 (2019): 413–426.
- 25U. Spiekerkoetter, M. L. Couce, A. M. Das, et al., “Long-Term Safety and Outcomes in Hereditary Tyrosinaemia Type 1 With Nitisinone Treatment: A 15-Year Non-Interventional, Multicentre Study,” The Lancet Diabetes and Endocrinology 9 (2021): 427–435.
- 26A. M. Das, “Clinical Utility of Nitisinone for the Treatment of Hereditary Tyrosinemia Type-1 (HT-1),” The Application of Clinical Genetics 10 (2017): 43–48.
- 27R. Bolia and A. Srivastava, “Liver Transplantation for Tyrosinemia Type 1 in the Developing World: Is It Really the Best We Can Offer?” Indian Journal of Pediatrics 89 (2022): 427–428.
- 28Y. Sanada, Y. Sakuma, Y. Onishi, et al., “Outcomes After Living Donor Liver Transplantation in Pediatric Patients With Inherited Metabolic Diseases,” Annals of Transplantation 26 (2021): e932994.
- 29R. Grenda and P. Kaliciński, “Combined and Sequential Liver-Kidney Transplantation in Children,” Pediatric Nephrology 33 (2018): 2227–2237.
- 30P. Sikora, M. Zaniew, R. Grenda, et al., “Still Diagnosed Too Late and Under-Recognized? The First Comprehensive Report on Primary Hyperoxaluria in Poland,” Polish Archives of Internal Medicine 130 (2020): 1053–1063.
- 31P. Cochat, S. A. Hulton, C. Acquaviva, et al., “Primary Hyperoxaluria Type 1: Indications for Screening and Guidance for Diagnosis and Treatment,” Nephrology, Dialysis, Transplantation 27 (2012): 1729–1736.
- 32R. Büscher, A. K. Büscher, M. Cetiner, et al., “Combined Liver and Kidney Transplantation and Kidney After Liver Transplantation in Children: Indication, Postoperative Outcome, and Long-Term Results,” Pediatric Transplantation 1 (2015): 858–865.
10.1111/petr.12595 Google Scholar
- 33A. Devresse, P. Cochat, N. Godefroid, and N. Kanaan, “Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives,” Kidney International Reports 5 (2020): 2136–2145.
- 34Y. Frishberg, G. Deschênes, J. W. Groothoff, et al., “Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial,” Clinical Journal of the American Society of Nephrology 16 (2021): 1025–1036.
- 35S. A. Hulton, J. W. Groothoff, Y. Frishberg, et al., “Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1,” Kidney International Reports 7 (2021): 494–506.
- 36S. F. Garrelfs, Y. Frishberg, S. A. Hulton, et al., “Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1,” The New England Journal of Medicine 384 (2021): 1216–1226.
- 37A. L. Sellier-Leclerc, E. Metry, S. Clave, et al., “Isolated Kidney Transplantation Under Lumasiran Therapy in Primary Hyperoxaluria Type 1: A Report of Five Cases,” Nephrology, Dialysis, Transplantation 38 (2023): 517–521.
- 38K. Ray, “Fazirsiran Shows Promise for Liver Disease in AAT,” Nature Reviews. Gastroenterology & Hepatology 19 (2022): 556.
- 39P. Strnad, M. Mandorfer, G. Choudhury, et al., “Fazirsiran for Liver Disease Associated With Alpha1-Antitrypsin Deficiency,” The New England Journal of Medicine 387 (2022): 514–524.
- 40A. Dhawan, R. M. Taylor, P. Cheeseman, P. De Silva, L. Katsiyiannakis, and G. Mieli-Vergani, “Wilson's Disease in Children: 37-Year Experience and Revised King's Score for Liver Transplantation,” Liver Transplantation 11 (2005): 441–448.
- 41J. Dana, D. Debray, A. Beaufrère, et al., “Cystic Fibrosis-Related Liver Disease: Clinical Presentations, Diagnostic and Monitoring Approaches in the Era of CFTR Modulator Therapies,” Journal of Hepatology 76 (2022): 420–434.
- 42M. D. Ayoub and B. M. Kamath, “Alagille Syndrome: Current Understanding of Pathogenesis, and Challenges in Diagnosis and Management,” Clinics in Liver Disease 26 (2022): 355–370.
- 43J. Menon, N. Shanmugam, M. Vij, A. Rammohan, and M. Rela, “Multidisciplinary Management of Alagille Syndrome,” Journal of Multidisciplinary Healthcare 15 (2022): 353–364.
- 44B. M. Kamath, A. Goldstein, R. Howard, et al., “Maralixibat Treatment Response in Alagille Syndrome Is Associated With Improved Health-Related Quality of Life,” The Journal of Pediatrics 252 (2023): 68–75.
- 45H. S. T. Muntaha, M. Munir, S. H. Sajid, et al., “Ileal Bile Acid Transporter Blockers for Cholestatic Liver Disease in Pediatric Patients With Alagille Syndrome: A Systematic Review and Meta-Analysis,” Journal of Clinical Medicine 11 (2022): 7526.
- 46B. L. Shneide, C. A. Spino, B. M. Kamath, et al., “Impact of Long-Term Administration of Maralixibat on Children With Cholestasis Secondary to Alagille Syndrome,” Hepatology Communications 6 (2022): 1922–1933.
- 47L. N. Bull and R. J. Thompson, “Progressive Familial Intrahepatic Cholestasis,” Clinics in Liver Disease 22 (2018): 657–669.
- 48S. Hassan and P. Hertel, “Overview of Progressive Familial Intrahepatic Cholestasis,” Clinics in Liver Disease 26 (2022): 371–390.
- 49I. Jankowska, P. Czubkowski, P. Kaliciński, et al., “Ileal Exclusion in Children With Progressive Familial Intrahepatic Cholestasis,” Journal of Pediatric Gastroenterology and Nutrition 58 (2014): 92–95.
- 50H. J. Verkade, R. J. Thompson, H. Arnell, et al., “Systematic Review and Meta-Analysis: Partial External Biliary Diversion in Progressive Familial Intrahepatic Cholestasis,” Journal of Pediatric Gastroenterology and Nutrition 71 (2020): 176–183.
- 51C. M. Hollands, F. J. Rivera-Pedrogo, R. Gonzalez-Vallina, O. Loret-de-Mola, M. Nahmad, and C. A. Burnweit, “Ileal Exclusion for Byler's Disease: An Alternative Surgical Approach With Promising Early Results for Pruritus,” Journal of Pediatric Surgery 33 (1998): 220–224.
- 52A. Mehl, H. Bohorquez, M. S. Serrano, G. Galliano, and T. W. Reichman, “Liver Transplantation and the Management of Progressive Familial Intrahepatic Cholestasis in Children,” World Journal of Transplantation 6 (2016): 278–290.
- 53S. M. Bedoyan, O. T. Lovell, S. P. Horslen, and J. E. Squires, “Odevixibat: A Promising New Treatment for Progressive Familial Intrahepatic Cholestasis,” Expert Opinion on Pharmacotherapy 23 (2022): 1771–1779.
- 54R. J. Thompson, H. Arnell, R. Artan, et al., “Odevixibat Treatment in Progressive Familial Intrahepatic Cholestasis: A Randomised, Placebo-Controlled, Phase 3 Trial,” The Lancet Gastroenterology & Hepatology 7 (2022): 830–842.
- 55J. Häberle, A. Burlina, A. Chakrapani, et al., “Suggested Guidelines for the Diagnosis and Management of Urea Cycle Disorders: First Revision,” Journal of Inherited Metabolic Disease 42 (2019): 1192–1230.
- 56J. Kido, S. Matsumoto, J. Häberle, et al., “Role of Liver Transplantation in Urea Cycle Disorders: Report From a Nationwide Study in Japan,” Journal of Inherited Metabolic Disease 44 (2021): 1311–1322.
- 57E. Szymańska, P. Kaliciński, J. Pawłowska, et al., “Polish Experience With Liver Transplantation and Post-Transplant Outcomes in Children With Urea Cycle Disorders,” Annals of Transplantation 22 (2017): 555–562.
- 58J. V. Lazarus, H. E. Mark, Q. M. Anstee, et al., “Advancing the Global Public Health Agenda for NAFLD: A Consensus Statement,” Nature Reviews. Gastroenterology & Hepatology 19 (2022): 60–78.
- 59I. Jankowska, P. Socha, J. Pawlowska, et al., “Recurrence of Non-Alcoholic Steatohepatitis After Liver Transplantation in a 13-Yr-Old boy,” Pediatric Transplantation 11 (2007): 796–798.
- 60J. de Ville de Goyet, U. Baumann, V. Karam, et al., “European Liver, Intestine Transplant Association. European Liver Transplant Registry: Donor and Transplant Surgery Aspects of 16,641 Liver Transplantations in Children,” Hepatology 75 (2022): 634–645.
- 61B. Dembowska-Bagińska, J. Więckowska, A. Brożyna, et al., “Health Status in Long-Term Survivors of Hepatoblastoma,” Cancers (Basel) 11 (2019): 1777.
- 62M. Honda, K. Uchida, T. Irie, et al., “Recent Advances in Surgical Strategies and Liver Transplantation for Hepatoblastoma,” Cancer Medicine 12 (2023): 3909–3918.
- 63H. Ismail, D. Broniszczak, P. Kaliciński, et al., “Changing Treatment and Outcome of Children With Hepatoblastoma: Analysis of a Single Center Experience Over the Last 20 Years,” Journal of Pediatric Surgery 47 (2012): 1331–1339.
- 64M. Stefanowicz, P. Kaliciński, H. Ismail, et al., “Risk for Recurrence in Long-Term Follow-Up of Children After Liver Transplantation for Hepatoblastoma or Hepatocellular Carcinoma,” Children (Basel) 11, no. 2 (2024): 193.
- 65P. Triana Junco, E. M. Cano, M. Dore, et al., “Prognostic Factors for Liver Transplantation in Unresectable Hepatoblastoma,” European Journal of Pediatric Surgery 29 (2019): 28–32.
- 66U. Baumann, R. Adam, C. Duvoux, et al., “European Liver and Intestine Transplant Association. Survival of Children After Liver Transplantation for Hepatocellular Carcinoma,” Liver Transplantation 24, no. 2 (2018): 246–255.
Citing Literature
